A Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for The Treatment of men and Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease

The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.

Primary Sponsor:
Novartis

Prinicipal Investigator:
Rebecca Kaltman, M.D./Medicine; Division of Hematology/Oncology

Contact Phone:
202-677-3379

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):